Frontiers in Immunology (Sep 2020)

Theta-Defensins Inhibit High-Risk Human Papillomavirus Infection Through Charge-Driven Capsid Clustering

  • Joseph G. Skeate,
  • Wouter H. Segerink,
  • Mauricio D. Garcia,
  • Daniel J. Fernandez,
  • Ruben Prins,
  • Kim P. Lühen,
  • Féline O. Voss,
  • Diane M. Da Silva,
  • Diane M. Da Silva,
  • W. Martin Kast,
  • W. Martin Kast,
  • W. Martin Kast

DOI
https://doi.org/10.3389/fimmu.2020.561843
Journal volume & issue
Vol. 11

Abstract

Read online

Persistent infection with high-risk human papillomavirus (hrHPV) genotypes results in a large number of anogenital and head and neck cancers worldwide. Although prophylactic vaccination coverage has improved, there remains a need to develop methods that inhibit viral transmission toward preventing the spread of HPV-driven disease. Defensins are a class of innate immune effector peptides that function to protect hosts from infection by pathogens such as viruses and bacteria. Previous work utilizing α and β defensins from humans has demonstrated that the α-defensin HD5 is effective at inhibiting the most common high-risk genotype, HPV16. A third class of defensin that has yet to be explored are θ-defensins: small, 18-amino acid cyclic peptides found in old-world monkeys whose unique structure makes them both highly cationic and resistant to degradation. Here we show that the prototype θ-defensin, rhesus theta defensin 1, inhibits hrHPV infection through a mechanism involving capsid clustering that inhibits virions from binding to cell surface receptor complexes.

Keywords